Chickenpox

Current Opinion in Infectious Diseases

Volumn 18, Issue 3, 2005, Pages 235-240

  Hambleton, Sophie ^a  

^a College of Physicians and Surgeons ^*  (United States)

Author keywords

Herpesvirus; Mannose 6 phosphate receptor; Vaccine; Varicella zoster

Indexed keywords

ANTIVIRUS AGENT; CHICKENPOX VACCINE; SOMATOMEDIN B RECEPTOR;

BACTERIAL ARTIFICIAL CHROMOSOME; CAUSE OF DEATH; CHICKENPOX; DECISION MAKING; DRUG EFFICACY; EPIDEMIOLOGICAL DATA; HERPES ZOSTER; HOSPITALIZATION; HUMAN; MOLECULAR CLONING; NONHUMAN; PATHOGENESIS; PUBLIC HEALTH; REVIEW; UNITED STATES; VACCINATION; VARICELLA ZOSTER VIRUS; VIRUS GENOME; VIRUS LATENCY; VIRUS REACTIVATION;

EID: 20044373072     PISSN: 09517375     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.qco.0000168384.31766.89     Document Type: Review

References (61)

1. Grose C, Ye M, Padilla JA. Pathogenesis of primary infection. In: Arvin AM, Gershon AA, editors. Varicella-zoster virus: virology and clinical management. Cambridge: Cambridge University Press; 2000 pp. 105-122.
2. Forghani B. Laboratory diagnosis of infection. In: Arvin AM, Gershon AA, editors. Varicella-zoster virus: virology and clinical management. Cambridge: Cambridge University Press; 2000. pp. 351-382.
3. Cook ML, Stevens J. Labile coat: reason for noninfectious cell-free varicella zoster virus in culture. J Virol 1968; 2:1458-1464.
4. ci-deficient cells are shown to be resistant to infection by enveloped virions, but when infected release infectious virus particles. Offers a plausible explanation for contagion via vesicular fluid.
5. Zhu Z, Gershon MD, Ambron R, et al. Infection of cells by varicella zoster virus: inhibition of viral entry by mannose 6-phosphate and heparin. Proc Natl Acad Sci U S A 1995; 92:3546-3550.
6. Gabel C, Dubey L, Steinberg S, et al. Varicella-zoster virus glycoproteins are phosphorylated during posttranslational maturation. J Virol 1989; 63:4264-4276.
7. Kornfeld S. Trafficking of lysosomal enzymes. FASEB J 1987; 1:462-468.
8. Arvin AM. Varicella-zoster virus. In: Fields BN, Knipe DM, Howley PM, editors. Fields Virology. 3rd ed. Philadelphia: Lippincott-Raven Press; 1996. pp. 2547-2586.
9. Feldman S, Epp E. Detection of viremia during incubation period of varicella. J Pediatr 1979; 94:746-748.
10. Mainka C, Fuss B, Geiger H, et al. Characterization of viremia at different stages of varicella-zoster virus infection. J Med Virol 1998; 56:91-98.
11. Ordonez G, Pineda B, Garcia-Navarrete R, Sotelo J. Brief presence of varicella-zoster viral DNA in mononuclear cells during relapses of multiple sclerosis. Arch Neurol 2004; 61:529-532. An intriguing finding, which follows earlier suggestions of an epidemiological link between varicella and multiple sclerosis in Mexico.
12. de Jong MD, Weel JF, van Oers MH, et al. Molecular diagnosis of visceral herpes zoster. Lancet 2001; 357:2101-2102.
13. Besser J, Ikoma M, Fabel K, et al. Differential requirement for cell fusion and virion formation in the pathogenesis of varicella-zoster virus infection in skin and T cells. J Virol 2004; 78:13293-13305. The SCID-hu mouse model is used to investigate the effect of mutations affecting envelopment; T cell infection appears to require virion production.
14. Moffat J, Ito H, Sommer M, et al. Glycoprotein I of varicella-zoster virus is required for viral replication in skin and T cells. J Virol 2002; 76:8468-8471.
15. Hindmarsh EJ, Staykova MA, Willenborg DO, Parish CR. Cell surface expression of the 300 kDa mannose-6-phosphate receptor by activated T lymphocytes. Immunol Cell Biol 2001; 79:436-443.
16. Ku CC, Padilla JA, Grose C, et al. Tropism of varicella-zoster virus for human tonsillar CD4(+) T lymphocytes that express activation, memory, and skin homing markers. J Virol 2002; 76:11425-11433.
17. Abendroth A, Morrow G, Cunningham AL, Slobedman B. Varicella-zoster virus infection of human dendritic cells and transmission to T cells: implications for virus dissemination in the host. J Virol 2001; 75:6183-6192.
18. Sadzot-Delvaux C, Merville-Louis M-P, Delree P, et al. An in vivo model of varicella-zoster virus latent infection of dorsal root ganglia. J Neurosci Res 1990; 26:83-89.
19. Cohen JI, Cox E, Pesnicak L, et al. The varicella-zoster virus open reading frame 63 latency-associated protein is critical for establishment of latency. J Virol 2004; 78:11833-11840. ORF63, the most abundantly expressed of the latency-associated proteins, is the first VZV gene shown to promote viral persistence in the cottonrat model.
20. Balker A, Fabel K, Cozzio A, et al. Varicella-zoster virus infection of human neural cells in vivo. Proc Natl Acad Sci U S A 2004; 101:10792-10797. The authors describe a new model in which to investigate neurotropic viruses such as VZV, which is shown to infect human neural cells engrafted into NOD-SCID mice.
21. Gray WL. Simian varicella: a model for human varicella-zoster virus infections. Rev Med Virol 2004; 14:363-381. A useful review of SVV.
22. Kennedy PG, Grinfeld E, Traina-Dorge V, et al. Neuronal localization of simian varicella virus DNA in ganglia of naturally infected African green monkeys. Virus Genes 2004; 28:273-276. Suggests that SW may establish latent infection in a manner similar to VZV.
23. Lungu O, Panagiotidis C, Annunziato P, et al. Aberrant intracellular localization of varicella-zoster virus regulatory proteins during latency. Proc Nat Acad Sci USA 1998; 95:7080-7085.
24. Grinfeld E, Kennedy P. Translation of varicella-zoster virus genes during human ganglionic latency. Virus Genes 2004; 29:317-319. Confirms the earlier work of Lungu et al. [23] describing the 'molecular signature' of latency.
25. Chen JJ, Gershon AA, Li ZS, et al. Latent and lytic infection of isolated guinea pig enteric and dorsal root ganglia by varicella zoster virus. J Med Virol 2003; 70:S71-S78.
26. Chen JJ, Wan S, Bischoff S, et al. VZV infection of human and animal enteric neurons: analysis of latency and reactivation. Abstract presented at the 29th International Herpesvirus Workshop, Reno, Nevada; 2004.
27. Nagaike K, Mori Y, Gomi Y, et al. Cloning of the varicella-zoster virus genome as an infectious bacterial artificial chromosome in Escherichia coli. Vaccine 2004; 22:4069-4074. Paper describing the construction of a VZV bacterial artificial chromosome, likely to accelerate the pace of VZV research considerably.
28. Takahashi M, Otsuka T, Okuno Y, et al. Live vaccine used to prevent the spread of varicella in children in hospital. Lancet 1974; 2:1288-1290.
29. Arvin AM. Varicella vaccine: genesis, efficacy, and attenuation. Virology 2001; 284:153-158.
30. Gomi Y, Imagawa T, Takahashi M, Yamanishi K. Oka varicella vaccine is distinguishable from its parental virus in DNA sequence of open reading frame 62 and its transactivation activity. J Med Virol 2000; 61:497-503.
31. Gomi Y, Sunamachi H, Mori Y, et al. Comparison of the complete DNA sequences of the Oka varicella vaccine and its parental virus. J Virol 2002; 76:11447-11459.
32. Quinlivan M, Gershon AA, Steinberg SP, Breuer J. An evaluation of single nucleotide polymorphisms used to differentiate vaccine and wild type strains of varicella-zoster virus. J Med Virol 2005; 75:174-180.
33. Quinlivan ML, Gershon AA, Steinberg SP, Breuer J. Rashes occurring after immunization with a mixture of viruses in the Oka vaccine are derived from single clones of virus. J Infect Dis 2004; 190:793-796. Demonstrates that, despite the fact that vOka is genotypically mixed, virus within individual vesicles is clonal.
34. WHO Expert Committee on Biological Standardization: forty-fourth report. WHO Expert Technical Report Series 848. Geneva: World Health Organization; 1994. http://www.who.int/biologicals/Guidelines/Vaccines.htm#C. [Accessed 31 January 2005].
35. Committee on Infectious Diseases. Recommendations for the use of live attenuated varicella vaccine. American Academy of Pediatrics. Pediatrics 1995; 95:791-796.
36. Centers for Disease Control. Prevention of varicella: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 1996; 45:1-36.
37. Centers for Disease Control. National, state, and urban area vaccination coverage among children aged 19-35 months: United States, 2003. Morb Mortal Wkly Rep 2004; 53:658-661.
38. Hambleton S, Gershon AA. Preventing varicella-zoster disease. Clin Microbiol Rev 2005; 18:70-80.
39. Hambleton S, Gershon AA. The impact of varicella vaccination in the United States. Semin Pediatr Infect Dis 2005; 16:38-43.
40. Vazquez M, LaRussa PS, Gershon AA, et al. Effectiveness over time of varicella vaccine. JAMA 2004; 291:851-855. Ongoing case-control study that now documents waning of the protective effect of vaccination beyond 12 months.
41. Vazquez M, LaRussa P, Gershon A, et al. The effectiveness of the varicella vaccine in clinical practice. N Engl J Med 2001; 344:955-960.
42. Lee BR, Feaver SL, Miller CA, et al. An elementary school outbreak of varicella attributed to vaccine failure: policy implications. J Infect Dis 2004; 190:477-483.
43. Tugwell BD, Lee LE, Gillette H, et al. Chickenpox outbreak in a highly vaccinated school population. Pediatrics 2004; 113:455-459. Both the above studies of varicella outbreaks found an increased risk of breakthrough varicella among children vaccinated 5 or more years previously.
44. Kuter B, Matthews H, Shinefield H, et al. Ten year follow-up of healthy children who received one or two injections of varicella vaccine. Pediatr Infect Dis J 2004; 23:132-137. Reports on a cohort immunized before vaccine licensure, and shows that a two-dose schedule gives superior protection against breakthrough varicella compared with a single dose.
45. Bernstein HH, Rothstein EP, Watson BM, et al. Clinical survey of natural varicella compared with breakthrough varicella after immunization with live attenuated Oka/Merck varicella vaccine. Pediatrics 1993; 92:833-837.
46. LaRussa P, Steinberg S, Shapiro E, et al. Viral strain identification in varicella vaccinees with disseminated rashes. Pediatr Infect Dis J 2000; 19:1037-1039.
47. Seward JF, Zhang JX, Maupin TJ, et al. Contagiousness of varicella in vaccinated cases: a household contact study. JAMA 2004; 292:704-708. A carefully executed study showing that mild breakthrough varicella is significantly less infectious than varicella in the unvaccinated, with implications for our understanding of outbreak epidemiology.
48. Davis MM, Patel MS, Gebremariam A. Decline in varicella-related hospitalizations and expenditures for children and adults after introduction of varicella vaccine in the United States. Pediatrics 2004; 114:786-792. Confirms that prevention of varicella in healthy children is leading to reduced rates of varicella complications.
49. Zhou F, Jumaan AO, Shefer A, Harpaz R. Impact of varicella vaccination on health care utilization in the United States, 1994-2001 [abstract]. Pediatr Res 2004; 55:200A.
50. Patel RA, Binns HJ, Shulman ST. Reduction in pediatric hospitalizations for varicella-related invasive group A streptococcal infections in the varicella vaccine era. J Pediatr 2004; 144:68-74. Shows a convincing decline in this feared complication of varicella, coinciding with increasing vaccine coverage.
51. McCoy L, Sorvillo F, Simon P. Varicella-related mortality in California, 1988-2000. Pediatr Infect Dis J 2004; 23:498-503. First published evidence of a trend towards declining varicella-related mortality following the introduction of vaccination.
52. Wise RP, Salive ME, Braun MM, et al. Postlicensure safety surveillance for varicella vaccine. JAMA 2000; 284:1271-1279.
53. Sharrar RG, LaRussa P, Galea S, et al. The postmarketing safety profile of varicella vaccine. Vaccine 2001; 19:916-923.
54. Rentier B, Gershon AA. Consensus: varicella vaccination of healthy children: a challenge for Europe. Pediatr Infect Dis J 2004; 23:379-389. The European Working Group on varicella reviews the evidence and recommends universal infant vaccination, provided very high coverage levels can be achieved.
55. Wagenpfeil S, Neiss A, Wutzler P. Effects of varicella vaccination on herpes zoster incidence. Clin Microbiol Infect 2004; 10:954-960. A good summary of the literature on herpes zoster in relation to varicella vaccine.
56. Hardy IB, Gershon A, Steinberg S, LaRussa P. The incidence of zoster after immunization with live attenuated varicella vaccine: a study in children with leukemia. N Engl J Med 1991; 325:1545-1550.
57. Gershon A, LaRussa P, Steinberg S, et al. The protective effect of immunologic boosting against zoster: an analysis in leukemic children who were vaccinated against chickenpox. J Infect Dis 1996; 173:450-453.
58. Thomas S, Wheeler J, Hall AJ. Contacts with varicella or with children and protection against herpes zoster in adults: a case-control study. Lancet 2002; 360:678-682.
59. Brisson M, Gay NJ, Edmunds WJ, Andrews NJ. Exposure to varicella boosts immunity to herpes-zoster: implications for mass vaccination, against chickenpox. Vaccine 2002; 20:2500-2507.
60. Levin M, Barber D, Goldblatt E, et al. Use of a live attenuated varicella vaccine to boost varicella-specific immune responses in seropositive people 55 years of age and older: duration of booster effect. J Infect Dis 1998; 178:S109-S112.
61. Levin MJ. Use of varicella vaccines to prevent herpes zoster in older individuals. Arch Virol Suppl 2001; 17:151-160.